top of page

Unleashing the
full potential of
existing medicines

Galenicap is a Belgian-Dutch privately held pharmaceutical development company focused on the development of improved versions of existing medicines (also known as value-added medicines), featuring enhanced efficacy or safety profiles, and potentially offering new therapeutic applications.  Our purpose is to deliver superior, cost-effective treatment alternatives to patients, while also presenting substantial opportunities for cost reduction to healthcare providers.

Product portfolio

Galenicap is on a mission to establish a world-class 'product engine' dedicated to the efficient launch and clinical validation of innovate drug reformulation and repurposing concepts.  Presently, we are engaged in 12 development programs, spanning a broad range of therapeutic indications including CNS, cardiovascular and infectious diseases, and women's health.

In contrast to most 505(b)(2) projects, which are often characterized by minimal product innovation, Galenicap focuses on pioneering solutions with substantial potential for true clinical impact

Everyone counts

Our vision is to deliver improvements to the healthcare community by increasing access to affordable and more patient-tailored medicines.

 

At Galenicap, we are dedicated to advancing our commitment to responsible business practices. Our focus on key pillars such as social impact and strong governance, underscores our dedication to health access, equitable medicine pricing, transparent leadership, and fostering diversity and inclusion.

We are proud to say that all our team members, collaborators, partners and shareholders share our values.

Latest news & events

Galenicap enters into drug reformulation program with Dutch university

March 28, 2024

Hans Platteeuw, Galenicap's CSO, to give keynote at Spark Europe Webinar "What is Drug Repurposing and Why is it Relevant"

January 29, 2024

Galenicap enters into drug reformulation co-development agreement with Germany pharma company

January 21, 2024

bottom of page